Becton, Dickinson and Company
) recently reported the commercialization of the BD FACSJazz Cell
Sorting System, a futuristic flow cytometer. This offering renders
the isolation and analysis of cells easier for researchers. The
sorter requires 20 inches by 20 inches of space and demonstrates
solid ability to recognize and isolate chosen cells.
According to the company, the BD FACSJazz Cell Sorting System will
support the quick progress in genomic studies in situations where
the integrity of the sample is important for next-generation
sequencing. The system is able to recognize and isolate either
individual or numerous cells and deposit the same in well plates in
a speedy and accurate manner. This sorter takes into account
comments from clients from a worldwide early access program held in
This system has novel features that make sorting an easier task.
One such feature is the pre-set optimal setting for accurate
targeting of cells. The BD FACSJazz Cell Sorting System may be
geared to handle 6 colors with 8 parameters. Its container has been
judged by the Baker Company to satisfy certain product and human
We nonetheless remain cautious about Becton Dickinson due to the
lack of major short-term catalysts. The rising demand for
safety-needle products (with higher price points and margins) was
the primary driver of the company's past growth, which is not
expected to continue, given that the U.S. market is already largely
On the positive side, Becton Dickinson's preeminent global
healthcare products franchise is partly insulated from volatile
macroeconomic conditions and structural deficiencies elsewhere in
the healthcare delivery field.
Becton Dickinson faces a wide range of competitors, including
) in certain niches, in each of its three business segments. We are
currently Neutral on the stock, supported by a short-term Zacks #3
BAXTER INTL (BAX): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis
To read this article on Zacks.com click here.